Surgery plus TKIs therapy for gastrointestinal stromal tumors

[1] Raut CP, Morgan JA, Ashley SW. Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease. Current opinion in gastroenterology. 2007;23:149–58. RautCP MorganJA AshleySW Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease Current opinion in gastroenterology 2007 23 149 58 Search in Google Scholar

[2] Chung JC, Kim HC, Hur SM. Limited resection for duodenal gastrointestinal stromal tumors and their oncologic outcomes. Surg Today. 2016;46:110–6. ChungJC KimHC HurSM Limited resection for duodenal gastrointestinal stromal tumors and their oncologic outcomes Surg Today 2016 46 110 6 Search in Google Scholar

[3] Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. Efficacy and safetyof imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80. DemetriGD von MehrenM BlankeCD Van den AbbeeleAD EisenbergB RobertsPJ HeinrichMC TuvesonDA SingerS JanicekM Efficacy and safetyof imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 2002 347 472 80 Search in Google Scholar

[4] Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al. Efficacy and safety of unitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–38. DemetriGD van OosteromAT GarrettCR BlacksteinME ShahMH VerweijJ McArthurG JudsonIR HeinrichMC MorganJA Efficacy and safety of unitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 2006 368 1329 38 Search in Google Scholar

[5] Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302. DemetriGD ReichardtP KangYK BlayJY RutkowskiP GelderblomH HohenbergerP LeahyM von MehrenM JoensuuH Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 2013 381 295 302 Search in Google Scholar

[6] Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325–31. RautCP PosnerM DesaiJ MorganJA GeorgeS ZahriehD FletcherCD DemetriGD BertagnolliMM Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 2006 24 2325 31 Search in Google Scholar

[7] Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, et al. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: A retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol. 2015;22:2948–57. Rubió-CasadevallJ Martinez-TruferoJ Garcia-AlbenizX CalabuigS Lopez-PousaA Del MuroJG FraJ RedondoA LainezN PovedaA Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: A retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS) Ann Surg Oncol 2015 22 2948 57 Search in Google Scholar

[8] Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G, Niebel W, Erhard J, Ebeling P, Zeth M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer. 2005;117:316–25. BauerS HartmannJT de WitM LangH GrabellusF AntochG NiebelW ErhardJ EbelingP ZethM Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib Int J Cancer 2005 117 316 25 Search in Google Scholar

[9] Zaydfudim V, Okuno SH, Que FG, Nagorney DM, Donohue JH. Role of operative therapy in treatment of tastatic gastrointestinal stromal tumors. J Surg Res. 2012;177:248–54. ZaydfudimV OkunoSH QueFG NagorneyDM DonohueJH Role of operative therapy in treatment of tastatic gastrointestinal stromal tumors J Surg Res 2012 177 248 54 Search in Google Scholar

[10] Bamboat ZM, DeMatteo RP. Metastasectomy for gastrointestinal stromal tumors. J Surg Oncol. 2014;109:23–7. BamboatZM DeMatteoRP Metastasectomy for gastrointestinal stromal tumors J Surg Oncol 2014 109 23 7 Search in Google Scholar

[11] Yeh CN, Chen TW, Tseng JH, Liu YY, Wang SY, Tsai CY, Chiang KC, Hwang TL, Jan YY, Chen MF. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol. 2010;102:599–603. YehCN ChenTW TsengJH LiuYY WangSY TsaiCY ChiangKC HwangTL JanYY ChenMF Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment J Surg Oncol 2010 102 599 603 Search in Google Scholar

[12] An HJ, Ryu MH, Ryoo BY, Sohn BS, Kim KH, Oh ST, Yu CS, Yook JH, Kim BS, Kang YK. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST. Ann Surg Oncol. 2013, 20:4212–8. AnHJ RyuMH RyooBY SohnBS KimKH OhST YuCS YookJH KimBS KangYK The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST Ann Surg Oncol 2013 20 4212 8 Search in Google Scholar

[13] Julio Sánchez-Meca, Juan Botella. Systematic reviews and metaanalyses: Tools for professional practice. Papeles del Psicólogo 2010, 31: 7–17. Sánchez-MecaJulio BotellaJuan Systematic reviews and metaanalyses: Tools for professional practice Papeles del Psicólogo 2010 31 7 17 Search in Google Scholar

[14] Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): Development and validation of a new instrument. ANZ J Surg. 2003;73:712–6. SlimK NiniE ForestierD KwiatkowskiF PanisY ChipponiJ Methodological index for non-randomized studies (MINORS): Development and validation of a new instrument ANZ J Surg 2003 73 712 6 Search in Google Scholar

[15] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–5. StangA Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses Eur J Epidemiol 2010 25 603 5 Search in Google Scholar

[16] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101. BeggCB MazumdarM Operating characteristics of a rank correlation test for publication bias Biometrics 1994 50 1088 101 Search in Google Scholar

[17] Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res Ed) 1997;315:629–34. EggerM DaveySG SchneiderM MinderC Bias in meta-analysis detected by a simple, graphical test BMJ (Clin Res Ed) 1997 315 629 34 Search in Google Scholar

[18] Chang SC, Liao CH, Wang SY, Tsai CY, Chiang KC, Cheng CT, Yeh TS, Chen YY, Ma MC, Liu CT, et al. Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib. Medicine (Baltimore). 2015;94:e1014. ChangSC LiaoCH WangSY TsaiCY ChiangKC ChengCT YehTS ChenYY MaMC LiuCT Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib Medicine (Baltimore) 2015 94 e1014 Search in Google Scholar

[19] Sato S, Tsujinaka T, Masuzawa T, Yamamoto K, Takahashi T, Yamashita Y, Fujita J, Takagi M, Hirota S, Nishida T. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry. Surg Today. 2017;47:58–64. SatoS TsujinakaT MasuzawaT YamamotoK TakahashiT YamashitaY FujitaJ TakagiM HirotaS NishidaT Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry Surg Today 2017 47 58 64 Search in Google Scholar

[20] Shi YN, Li Y, Wang LP, Wang ZH, Liang XB, Liang H, Zhang L, Li B, Fan LQ, Zhao Q, et al. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China. Medicine (Baltimore). 2017;96:e8240. ShiYN LiY WangLP WangZH LiangXB LiangH ZhangL LiB FanLQ ZhaoQ Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China Medicine (Baltimore) 2017 96 e8240 Search in Google Scholar

[21] Xiao B, Peng J, Tang J, Zhang R, Li C, Lin J, Ding P, Wan D, Pan Z, Wu X. Liver surgery prolongs the survival of patients with gastrointestinal stromal tumor liver metastasis: a retrospective study from a single center. Cancer Manag Res. 2018;10:6121–7. XiaoB PengJ TangJ ZhangR LiC LinJ DingP WanD PanZ WuX Liver surgery prolongs the survival of patients with gastrointestinal stromal tumor liver metastasis: a retrospective study from a single center Cancer Manag Res 2018 10 6121 7 Search in Google Scholar

[22] Xia L, Zhang MM, Ji L, Li X, Wu XT. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today. 2010;40:936–42. XiaL ZhangMM JiL LiX WuXT Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors Surg Today 2010 40 936 42 Search in Google Scholar

[23] Xue A, Gao X, He Y, Shu P, Huang X, Sun J, Lu J, Hou Y, Fang Y, Shen K. Role of Surgery in the Management of Liver Metastases From Gastrointestinal Stromal Tumors. Front Oncol. 2022;12:903487. XueA GaoX HeY ShuP HuangX SunJ LuJ HouY FangY ShenK Role of Surgery in the Management of Liver Metastases From Gastrointestinal Stromal Tumors Front Oncol 2022 12 903487 Search in Google Scholar

[24] Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ. Is there a role for surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding toimatinib: A prospective randomised trial in China. Eur J Cancer 2014,50:1772–8. DuCY ZhouY SongC WangYP JieZG HeYL LiangXB CaoH YanZS ShiYQ Is there a role for surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding toimatinib: A prospective randomised trial in China Eur J Cancer 2014 50 1772 8 Search in Google Scholar

[25] Gao X, Xue A, Fang Y, Shu P, Ling J, Qin J, Hou Y, Shen K, Sun Y, Qin X. Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib. Sci Rep. 2016;6:22840. GaoX XueA FangY ShuP LingJ QinJ HouY ShenK SunY QinX Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib Sci Rep 2016 6 22840 Search in Google Scholar

[26] Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Fiore M, Hohenberger P, Gronchi A. Post-imatinib surgery in advanced/metastaticGIST: Is it worthwhile in all patients? Ann Oncol. 2010;21:403–8. MussiC RonellenfitschU JakobJ TamboriniE ReichardtP CasaliPG FioreM HohenbergerP GronchiA Post-imatinib surgery in advanced/metastaticGIST: Is it worthwhile in all patients? Ann Oncol 2010 21 403 8 Search in Google Scholar

[27] Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093. Debiec-RychterM SciotR Le CesneA SchlemmerM HohenbergerP van OosteromAT BlayJY LeyvrazS StulM CasaliPG KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Eur J Cancer 2006 42 1093 Search in Google Scholar

[28] Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26:5360. HeinrichMC OwzarK CorlessCL HollisD BordenEC FletcherCD RyanCW von MehrenM BlankeCD RankinC Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group J Clin Oncol 2008 26 5360 Search in Google Scholar

[29] Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342. HeinrichMC CorlessCL DemetriGD BlankeCD von MehrenM JoensuuH McGreeveyLS ChenCJ Van den AbbeeleAD DrukerBJ Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 2003 21 4342 Search in Google Scholar

[30] Hasegawa J, Kanda T, Hirota S, Fukuda M, Nishitani A, Takahashi T, Kurosaki I, Tsutsui S, Hatakeyama K, Nishida T. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol. 2007;12:212–7. HasegawaJ KandaT HirotaS FukudaM NishitaniA TakahashiT KurosakiI TsutsuiS HatakeyamaK NishidaT Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy Int J Clin Oncol 2007 12 212 7 Search in Google Scholar

[31] Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib: Analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014;40:412–9.. BauerS RutkowskiP HohenbergerP MiceliR FumagalliE SiedleckiJA NguyenBP KerstM FioreM NyckowskiP Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib: Analysis of prognostic factors (EORTC-STBSG collaborative study) Eur J Surg Oncol 2014 40 412 9 Search in Google Scholar

[32] Chen Q, Li C, Yang H, Zhao H, Wu J, Zhao J, Bi X, Li Z, Huang Z, Zhang Y, et al. Resection Combined with TKI Therapy for Resectable Liver Metastases of Gastrointestinal Stromal Tumours: Results from Three National Centres in China. J Gastrointest Surg. 2020;24:1330–41. ChenQ LiC YangH ZhaoH WuJ ZhaoJ BiX LiZ HuangZ ZhangY Resection Combined with TKI Therapy for Resectable Liver Metastases of Gastrointestinal Stromal Tumours: Results from Three National Centres in China J Gastrointest Surg 2020 24 1330 41 Search in Google Scholar

[33] Turley RS, Peng PD, Reddy SK, Barbas AS, Geller DA, Marsh JW, Tsung A, Pawlik TM, Clary BM. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer. 2012;118:3571–8. TurleyRS PengPD ReddySK BarbasAS GellerDA MarshJW TsungA PawlikTM ClaryBM Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era Cancer 2012 118 3571 8 Search in Google Scholar

[34] Kraft A, Croitoru A, Gheorghe C, Lupescu I, Grasu M, Tomescu D, Droc G, Herlea V, Barcu A, Popescu I, et al. Liver Resection for Metastases from Gastrointestinal Stromal Tumors: Does it Improve Long-Term Survival? Chirurgia (Bucur). 2021;116:438–50. KraftA CroitoruA GheorgheC LupescuI GrasuM TomescuD DrocG HerleaV BarcuA PopescuI Liver Resection for Metastases from Gastrointestinal Stromal Tumors: Does it Improve Long-Term Survival? Chirurgia (Bucur) 2021 116 438 50 Search in Google Scholar

[35] Seesing MF, Tielen R, van Hillegersberg R, van Coevorden F, de Jong KP, Nagtegaal ID, Verhoef C, de Wilt JH; Dutch Liver Surgery Working Group. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study. Eur J Surg Oncol. 2016;42:1407–13. SeesingMF TielenR van HillegersbergR van CoevordenF de JongKP NagtegaalID VerhoefC de WiltJH Dutch Liver Surgery Working Group Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study Eur J Surg Oncol 2016 42 1407 13 Search in Google Scholar